MODERN VIEW ON CARDIOTOXICITY OF CHEMOTHERAPEUTICS IN ONCOLOGY INCLUDING ANTHRACYCLINES
High efficacy of contemporary chemical and radiation treatments made it to success in treatment of oncohematological diseases. The fundamentals of many schemes of polychemotherapy of the first line are anthracyclines. Effective treatment of the main disease in many cases is followed by a variety of cardiovascular  complications, including severe ones and fatal. It is necessary to consider the possibility not only for development  of acute cardiotoxicity, but various complications from cardiovascular system  after cessation of antitumor treatment. Algorithm of patients  preparing  for such treatment must include cardiovascular  assessment before the start of drugs, and follow-up during the treatment course. Prevention and treatment of cardiotoxicity are complicated clinical issues due to irreversible and progressing character of most disorders  of cardiovascular  system.  An important issue  is a close collaboration of cardiologist and oncologist in patient's management. It is necessary to have longterm  dynamic  follow-up of  patients   after  chemotherapy  for  maximally early diagnostics   of cardiovascular   complications  in long-term  period  after  finishing of antitumor treatment.